Search Results

Darbepoetin-α lacks efficacy and may cause stroke

Source: Reactions, Volume 1, Number 1277, 2009-11-07 , pp. 2-2(1)

Publisher: Adis International

It can be important to include clinical variables not found in claims data when carrying out propensity score matching

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 591, 2009-11-14 , pp. 13-13(1)

Publisher: Adis International

The Importance of Clinical Variables in Comparative Analyses Using Propensity-Score Matching: The Case of ESA Costs for the Treatment of Chemotherapy-Induced Anaemia

Authors: Polsky, Daniel; Eremina, Daria; Hess, Gregory; Hill, Jerrold; Hulnick, Scott; Roumm, Adam; Whyte, Joanna L.; Kallich, Joel

Source: PharmacoEconomics, Volume 27, Number 9, 1 September 2009 , pp. 755-765(11)

Publisher: Adis International

Every-Other-Week Darbepoetin Alfa in the Correction and Maintenance of Haemoglobin Levels in Elderly Patients with Chronic Kidney Disease: Post Hoc Subanalysis of Data from Two Clinical Trials

Authors: Krause, Michelle W.; Raja, Rasib; Agarwal, Anil; Silver, Marcia R.; Scarlata, Debra; Sciarra, Angela; Kewalramani, Reshma

Source: Drugs & Aging, Volume 26, Number 8, 1 August 2009 , pp. 665-675(11)

Publisher: Adis International

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia*

Authors: Hernandez, Enrique; Ganly, Peter; Charu, Veena; DiBenedetto, Joseph; Tomita, Dianne; Lillie, Tom; Taylor, Kerry; for the ARANESP 20030232 Study Group,

Source: Current Medical Research and Opinion, Volume 25, Number 9, September 2009 , pp. 2109-2120(12)

Publisher: Informa Healthcare

Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients

Authors: KIM, CHAN-DUCK; PARK, SUN-HEE; KIM, DAE-JOONG; PARK, JONG-WON; DO, JUN-YOUNG; SHIN, SUK-KYUN; KIM, BEOM-SEOK; SEO, JUNG-JU; KIM, YONG-LIM

Source: Nephrology, Volume 14, Number 5, August 2009 , pp. 482-487(6)

Publisher: Blackwell Publishing

Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?

Author: Schmidt, Rebecca J

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 9, June 2009 , pp. 1509-1514(6)

Publisher: Informa Healthcare

Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents*

Authors: Silver, M. R.; Geronemus, R.; Krause, M.; Chen, C. Y.; Kewalramani, R.; Stehman-Breen, C.

Source: Current Medical Research and Opinion, Volume 25, Number 1, January 2009 , pp. 123-131(9)

Publisher: Informa Healthcare

Use and cost of erythropoiesis-stimulating agents in patients with cancer

Authors: Daniel, Gregory; Hurley, Dana; Whyte, Joanna L.; Willey, Vincent; Wilson, Marcus; Kallich, Joel

Source: Current Medical Research and Opinion, Volume 25, Number 7, July 2009 , pp. 1775-1784(10)

Publisher: Informa Healthcare

The cumulative costs using epoetin-α are 29% lower than those using darbepoetin-α in cancer chemotherapy patients

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 579, 2009-05-30 , pp. 12-12(1)

Publisher: Adis International

Balancing act required when considering ESAs for cancer-related anaemia

Source: Reactions, Volume 1, Number 1251, 2009-05-09 , pp. 1-1(1)

Publisher: Adis International

Dapsone: Haemolysis and haemolytic anaemia in an elderly patient, controlled with darbepoetin α: case report

Source: Reactions, Volume 1, Number 1245, 2009-03-28 , pp. 15-15(1)

Publisher: Adis International

Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts

Author: Jelkmann, W.

Source: Current Medicinal Chemistry, Volume 16, Number 10, April 2009 , pp. 1236-1247(12)

Publisher: Bentham Science Publishers

Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration

Authors: Kawakami, Kazuki; Takama, Hirotaka; Nakashima, Daisuke; Tanaka, Hideji; Uchida, Eiji; Akizawa, Tadao

Source: European Journal of Clinical Pharmacology, Volume 65, Number 2, February 2009 , pp. 169-178(10)

Publisher: Springer

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

Authors: Wauters, Isabelle; Vansteenkiste, Johan

Source: Expert Opinion on Biological Therapy, Volume 9, Number 2, February 2009 , pp. 221-230(10)

Publisher: Informa Healthcare

A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study

Authors: Bommer, Juergen; Asmus, Gernot; Wenning, Martin; Bommer, Gudrun

Source: Nephrology Dialysis Transplantation, Volume 23, Number 12, 30 December 2008 , pp. 4002-4008(7)

Publisher: Oxford University Press

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study

Authors: Canaud, Bernard; Mingardi, Giulio; Braun, Johann; Aljama, Pedro; Kerr, Peter G.; Locatelli, Francesco; Villa, Giuseppe; Van Vlem, Bruno; McMahon, Alan W.; Kerloguen, Ccile; Beyer, Ulrich

Source: Nephrology Dialysis Transplantation, Volume 23, Number 11, 19 November 2008 , pp. 3654-3661(8)

Publisher: Oxford University Press

A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

Authors: Mel, J.R.; Salar, A.; Rodríguez, C.A.; Alegre, A.; González, A.; Cassinello, J.; Montesinos, J.; Gasquet, J.A.; Sánchez, J.; Saigí, E.; AMG-DAR-2002-01 StudyGroup,

Source: Current Medical Research and Opinion, Volume 24, Number 10, October 2008 , pp. 2931-2942(12)

Publisher: Informa Healthcare

The Costs of Drugs Used to Treat Myelodysplastic Syndromes Following National Comprehensive Cancer Network Guidelines

Authors: Greenberg, Peter L.; Cosler, Leon E.; Ferro, Salvatore A.; Lyman, Gary H.

Source: Journal of the National Comprehensive Cancer Network (JNCCN), Volume 6, Number 9, October 2008 , pp. 942-953(12)

Publisher: Cold Spring Publishing, LLC

Change in Darbepoetin Alfa Administration Schedule Affects Erythropoiesis-Stimulating Agent Resistance in Patients with Chronic Kidney Disease Receiving Hemodialysis

Authors: Molina, Manuel; Navarro, Maria Jose; de Gracia, Carmen; Alvarez, Gracia; de Alarcon, Rosa; Garcia, Maria Angeles

Source: Renal Failure, Volume 30, Number 8, September 2008 , pp. 778-783(6)

Publisher: Informa Healthcare